Brigatinib
Brigatinib-3001
Phase 3 small_molecule completed
Quick answer
Brigatinib for ALK+ Advanced NSCLC is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- ALK+ Advanced NSCLC
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed